Skip to main content
main-content

15-09-2017 | ESMO 2017 | Video

Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC

Lead investigator Suresh Ramalingam discusses the practice-changing results of the FLAURA study pitting osimertinib against gefitinib or erlotinib in the first-line advanced NSCLC setting.

Read the related news story here.

Please log in to get access to this content

Background information for this content